Transpharmation is working with the British Pharmacological Society, (BPS) to bring you this 3 part webinar series to address the drug discovery process of rapid acting antidepressants both pre-clinically and clinically. Taking ketamine as a first example and moving on to examine the rapidly expanding field of psychedelic research, issues around translatability with ketamine as a reference point to compare similarities and differences. In the third webinar we will look to the future and where things are likely to be in the coming years. Guest speakers will be joining us on each of the dates.
Webinar 1: KETAMINE; TRAILBLAZER AND STILL RELEVANT PLAYER
Webinar 2: PSYCHEDELICS; PRECLINICAL TRIALS AND TRANSLATABILITY
Webinar 3: PSYCHEDELICS; IN THE CLINIC, FUTURE DIRECTIONS
As sponsors of this event we are looking forward to attending. We will be presenting two pieces of work with our sister company InterVivo Solutions. This conference focuses on drug discovery for proteopathic neurodegenerative diseases, new disease models, latest technologies and innovative targets.
Read our abstracts here:
We look forward to seeing you at the event.
More information about the event can be found here: https://www.neuro4d.com/
Transpharmation is proud to be one of the sponsors for this 22nd annual conference which focuses on the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments and use of VR and Medical Devices that carry out non-invasive nerve stimulation. We’ll be hosting a booth with our sister company InterVivo Solutions. Christina de Rivera, Chief Scientific Officer at InterVivo Solutions, will be presenting on 5th May at 9.50am - more details to follow on the topic of The Aged Beagle Dog Model of Osteoarthritis.
For more detail about this event click here: https://smi-online.co.uk/pharmaceuticals/uk/pain-therapeutics
With preclinical/clinical transition being the largest failure risk in CNS therapeutics development, Transpharmation will be revealing new scientific development work at the 2022 HubXchange’s CNS Therapeutics West Coast roundtable meeting, where senior drug developers from pharma and biotech share experiences and discuss the future research landscape. More details about the topics of discussion and event location to follow.
Click on this link to read about hubXchange: https://www.hub-xchange.com/about-us/
AD/PD™ 2022 brings a new look and a new chapter in the history of the AD/PD™ series of conferences. By merging together with the AAT-AD/PD™ Advances in Alzheimer’s Therapies Focus Meeting, AD/PD™ is now transformed into an annual meeting, with a continuing focus on the advances in science and therapy of Alzheimer’s and Parkinson’s Diseases and related neurological disorders.
One of Transpharmation's scientists, Caoimhe Tyndall will be presenting a poster titled 'Assessing the immunogenicity of alpha-synuclein oligomers,filaments and fibrils in a clinically relevant model of synucleinopathy in-vitro' (poster P529) at our virtual booth.InterVivo Solutions, who Transpharmation merged with in January this year, will be hosting an in-person booth at this conference in Barcelona. Whichever you decide to attend, we look forward to seeing you!
For further information on this event click here: https://adpd.kenes.com/
To read about the merger click here: https://www.transpharmation.co.uk/news/intervivo-solutions-and-transpharmation-join-forces-as-sister-companies
Now that the event is over, we have made our poster presentation available for you to view here: View Poster